Clinical Trials
29 trialsRAVEN
UNC Lineberger Comprehensive Cancer Center
REVIVAL
AbbVie
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
OHSU Knight Cancer Institute
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
VAH vs VA in Newly Diagnosed Elderly AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
VHAG
First People's Hospital of Hangzhou
VAG-3+7-G
Institute of Hematology & Blood Diseases Hospital, China
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
The First Affiliated Hospital of Soochow University
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
VENP-A-QUI
PETHEMA Foundation
MDS
Thomas Jefferson University
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Hoosier Cancer Research Network
MIVONU
French Innovative Leukemia Organisation
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
The Methodist Hospital Research Institute
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
GAVEL
Dana-Farber Cancer Institute
FIT-AML
European Organisation for Research and Treatment of Cancer - EORTC
Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax
Peking University People's Hospital
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
University of Iowa
Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
SEVENAZA
Gustave Roussy, Cancer Campus, Grand Paris
Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.
Ruijin Hospital
AZA+Lus VS AZA Monotherapy in HR-MDS
Peking Union Medical College Hospital
Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Dragon
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
VA as Maintenance Therapy Post Allo-HSCT in MDS and AML
Navy General Hospital, Beijing
CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
Navy General Hospital, Beijing
ERASE
Eastern Cooperative Oncology Group
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
Akeso